Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.56 EUR | +2.40% | +2.40% | +6.22% |
Apr. 22 | BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment | MT |
Apr. 11 | Gerresheimer shares down on outlook, but key contracts confirmed | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.22% | 38.67M | |
-10.51% | 292M | |
-.--% | 62.2M | |
-20.59% | 60.47M |
- Stock Market
- Equities
- ADMIN Stock
- News Administer Oyj
- Arch Biopartners on Pre-IND Meeting With FDA to Repurpose Cilastatin as New Treatment to Prevent Acute Kidney Injury